NCT00247663View on ClinicalTrials.gov

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

December 31, 2005

Conditions
Postmenopausal Women With Advanced Breast Cancer
Interventions
DRUG

Letrozole

Trial Locations (10)

277-8577

Novartis Investigative Site, Kashiwa

660-8511

Novartis Investigative Site, Amagasaki

430-8558

Novartis Investigative Site, Hamamatsu

104-0045

Novartis Investigative Site, Chuo-Ku

104-8560

Novartis Investigative Site, Cyuo-ku

160-8582

Novartis Investigative Site, Shinjuku-ku

811-4395

Novartis Investigative Site, Fukuoka

862-0909

Novartis Investigative Site, Kumamoto

951-8566

Novartis Investigative Site, Nigata-honmachi

338-8553

Novartis Investigative Site, Saitama

Sponsors

Collaborators (1)

Chugai Pharmaceutical
All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

lead

Novartis Pharmaceuticals

INDUSTRY

NCT00247663 - Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer | Biotech Hunter | Biotech Hunter